Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial

Multiple Myeloma (MM)

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Lancet Haematol

Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Puła A, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ

doi: 10.1016/S2352-3026(26)00011-6

Multiple Myeloma (MM)

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Br J Haematol

Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O

doi: 10.1111/bjh.70642

Multiple Myeloma (MM)

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Lancet Oncol

Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T

doi: 10.1016/S1470-2045(25)00280-3

Multiple Myeloma (MM)

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Blood Cancer J

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros A

doi: 10.1038/s41408-025-01355-0

Multiple Myeloma (MM)

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant

Br J Haematol

Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S

doi: 10.1111/bjh.70359

Further Publications

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial

Lancet Haematol

Wu H, Shi W, Shi Z, Luo Y, Yu J, Cao W, Cao J, Xu X, Hu X, Lu Y, Fu H, Liu L, Lai X, Yang L, Ye Y, Zhang C, Shi J, Huang H, Zhao Y

doi: 10.1016/S2352-3026(26)00167-5

Lung, Respiratory and Thoracic Cancer

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Lancet Oncol

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L

doi: 10.1016/S1470-2045(26)00282-2

Gastrointestinal Cancer

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis

Lancet Oncol

Quik JSE, Vollebergh MA, Retèl VP, van der Sluis K, Koemans WJ, van der Kaaij RT, Voets MM, Luyer MDP, van Hellemond IEG, Wijnhoven BPL, Mostert B, van Hillegersberg R, Mohammad NH, van Etten B, de Groot DJ, Helminen O, Hedberg J, Cashin PH, Harbjerg JL, Veenhof AAFA, Hartemink KJ, Kodach LL, van der Noort V, van Sandick JW, PERISCOPE II consortium

doi: 10.1016/S1470-2045(26)00144-0

Lymphoma

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

J Clin Oncol

Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J

doi: 10.1200/JCO-25-01957

Related content

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial